Cargando…
Metastatic follicular dendritic cell sarcoma treated with gemcitabine plus docetaxel with an outstanding survival: A case report and review of literature
Follicular dendritic cell sarcoma responded dramatically to chemotherapy with gemcitabine and docetaxel.
Autores principales: | Esmati, Ebrahim, Kolahdouzan, Kasra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813082/ https://www.ncbi.nlm.nih.gov/pubmed/33489199 http://dx.doi.org/10.1002/ccr3.3560 |
Ejemplares similares
-
Response of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review
por: Conry, Robert M
Publicado: (2014) -
Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022) -
Evaluation of Survival Rate and Associated Factors in Patients with Cervical Cancer: A Retrospective Cohort Study
por: Tabatabaei, Fatemeh-Sadat, et al.
Publicado: (2022) -
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
por: Pender, Alexandra, et al.
Publicado: (2018) -
Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)